Unmanipulated haploidentical transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy) represents an alternative for patients with high-risk diseases lacking HLA-identical donor. Although it provides low incidences of GVHD, the efficacy of Haplo-SCT is still questioned, especially for patients with myeloid malignancies. Thus, we analyzed 60 consecutive patients with refractory (n = 30) or high-risk CR (n = 30) AML or myelodysplastic syndromes (MDSs) who underwent PT-Cy Haplo-SCT. The median age was 57 years (22-73 years), hematopoietic cell transplantation comorbidity index was ⩾ 3 in 38 patients (63%) and Haplo-SCT was the second allogeneic transplantation for 10 patients (17%). Although most of patients received PBSC as graft source (n = 48, 80%), we found low incidences of grade 3-4 acute (2%) and severe chronic GVHD (4%). Among patients with high-risk CR diseases, 1-year non-relapse mortality, cumulative incidence of relapse, progression-free and overall survivals were 20%, 32%, 47% and 62%, respectively. In patients with refractory disease, corresponding results were 34%, 35%, 32% and 37%, respectively. We conclude that PT-Cy Haplo-SCT could provide promising anti-leukemic effect even in the setting of very advanced diseases. Thus, it represents a viable alternative for high-risk AML/MDS patients without HLA-identical donor.
INTRODUCTION
Haploidentical allogeneic transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy) allowed low incidences of severe acute and chronic GVHD to be achieved. This lead to an incidence of non-relapse mortality (NRM) approaching what was observed in the setting of HLA-identical allogeneic transplantation (Allo-SCT).
1,2 Thus, Haplo-SCT may represent a feasible alternative for patients without an HLA-identical donor, overcoming the issue of donor availability. In contrast, previous series reported a higher incidence of relapse after Haplo-SCT, especially in patients suffering from myeloid diseases. 1, 3 However, it is not known if this is related to the Haplo-SCT procedure itself or to the high risk of the diseases, usually included in the previous reports. Moreover, most of data on PT-Cy Haplo-SCT included various diagnoses of hematological malignancies, making difficult the accurate evaluation of the efficacy for specific diseases. Although some reports specifically addressed this question for lymphoid diseases, [4] [5] [6] few data of PT-Cy Haplo-SCT for AML or myelodysplastic syndromes (MDSs) are available so far. Therefore, we investigated the outcome of patients with refractory or high-risk CR AML or MDS undergoing PT-Cy Haplo-SCT in a joint bi-institutional transplantation program.
MATERIALS AND METHODS

Selection criteria
Patients with the following criteria were included for analysis: (1) Haplo-SCT from 2010 to 2014 in two centers (Institut Paoli Calmettes, Marseille, France; Humanitas Cancer Center, Rozzano, Italy); (2) absence of matched related or unrelated donor; (3) high-risk AML or MDS as defined below; (4) PT-Cy as part of GVHD prophylaxis after T-replete PBSC or bone marrow (BM) Haplo-SCT.
High-risk diseases and treatment strategy
According to our institutional guidelines, AML or MDS patients were indicated for Haplo-SCT in the absence of matched related or unrelated donor in case of refractory disease or at least one of following criteria defining high-risk CR: (1) CR1 AML with unfavorable cytogenetics according to the European LeukemiaNet (ELN) classification; 7 (2) CR1 AML following acute transformation of MDS occurring during the treatment of MDS; (3) CR2 or more advanced CR AML; (4) high-risk International Prognostic Scoring System (IPSS) MDS in CR after intensive induction chemotherapy or demethylating agent. 8 
Conditioning regimens and GVHD prophylaxis
Conditioning regimens are detailed in Supplementary File 1. Initially, our Haplo-SCT program started using a non-myeloablative conditioning regimen based on the Baltimore schema (fludarabine+cyclophosphamide +TBI 2 Gray). 1 Then, the intensity of conditioning regimen was progressively increased by using intravenous busulfan (bu) rather than low-dose TBI, aiming to improve anti-leukemic effect in high-risk patients. This bu-based platform was also modified over time, with a progressive increase of the busulfan doses and the replacement of pre-transplantation cyclophosphamide by thiotepa. Finally, we progressively enrolled patients in our program of sequential approach for refractory AML, using a bu-based reduced intensity conditioning (RIC) regimen given 10 days after the start of a debulking intensive chemotherapy based on fludarabine, idarubicin and cytarabine.
GVHD prophylaxis consisted in 50 mg/kg PT-Cy at day +3 and +4 after Haplo-SCT. Additional post-transplantation immunosuppressive agents (mycophenolate mofetil plus either cyclosporine A (CsA) or FK506) were given starting on day +5. Mycophenolate mofetil was stopped at day +35, whereas CsA or FK506 was progressively tapered from day +120 to day +180. All patients received granulocyte colony-stimulating factor (G-SCF) starting on day +5.
Statistical analyses
We reported the outcome according to classical end points for the overall population. Moreover, because disease status is a major parameter for the interpretation of outcome, we decided to separately present the results of patients with high-risk CR or refractory status. Cumulative incidences taking into account competing risk were calculated using the Prentice method and Fine & Gray test. 9, 10 Relapse and death in the absence of disease progression were considered as mutually competing events in the calculation of the cumulative incidences of relapse and non-relapse mortality (NRM). The cumulative incidences of both acute and chronic GVHD considered deaths before GVHD as competing events. Glucksberg and NIH classifications were used for the gradation of acute and chronic GVHD, respectively.
11,12 PFS and overall survival (OS) were calculated using common Kaplan-Meier estimator and were compared using Log Rank test. 13 As we previously reported, we analyzed a composite end point considering relapse, death and the occurrence of grade 3-4 acute and moderate+severe chronic GVHD as relevant events. 14 The pertinence of this GVHD and relapse-free survival (GRFS) to evaluate the overall outcome after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) integrating a quality of life assessment was recently confirmed. 15 Statistics were computed using R-project 3.1.3 software (www.r-project.org).
RESULTS
Patient and transplantation characteristics
The baseline characteristics of the 60 consecutive included patients with a median age was 57 years (22-73 years) are reported in Table 1 , dichotomized according to disease status at the time of Haplo-SCT. Briefly, 27 patients were 60 years of age or more (45%) and hematopoietic cell transplantation comorbidity index (HCT-CI) 16 was ⩾ 3 in 38 patients (63%). Half of patients (n = 30) presented with refractory disease at the time of Haplo-SCT. Among the 30 patients transplanted in CR, all were considered at high risk because of adverse cytogenetics, relapsed AML or acute transformation of a MDS during the initial treatment. Moreover, Haplo-SCT was the second Allo-HSCT for 10 patients (17%, 9 for relapse and 1 for graft failure). Most of the patients received PBSC as the graft source (n = 48, 80%) and CsA plus mycophenolate mofetil as additional GVHD prophylaxis to PT-Cy (n = 53, 88%). In all, 20 (33%) and 40 patients were given nonmyeloablative conditioning TBI-based and bu-based regimen, respectively. Median infused CD34 + cell dose was 4.5x10 6 /kg (1.6-14.8). Anti-infectious prophylaxes were used as previously described. Abbreviations: Allo-HSCT = allogeneic hematopoietic stem cell transplantation; AML = acute myeloid leukemia; BM = bone marrow; CR = complete remission; HCT-CI = hematopoietic cell transplantation comorbidity index; MDS = myelodysplastic syndrome; PBSC = peripheral blood stem cells; TBI = total body irradiation. Cumulative incidences of grade 2-4 and 3-4 acute GVHD at day +100 were 18% and 2%, respectively, whereas cumulative incidences of all grades and severe chronic GVHD at 1 year were 14% and 4%, respectively (Figures 1a and b) . Outcome after Haplo-SCT are reported in Table 2 . Death without evidence of disease progression occurred in a median time of 77 days after Haplo-SCT (range: 3-220 days), leading to a cumulative incidence of NRM at 1 year of 27%. Only two non-relapse deaths occurred after 6 months following Haplo-SCT. We found no difference in Abbreviations: 95% CI = confidence interval at 95%; CR = complete remission; Haplo-SCT = haploidentical allogeneic transplantation; GRFS = GVHD and relapse-free survival. 1-year NRM according to age (age ⩽ 60 vs 460 years: 29% vs 26%, P = 0.837) or HCT-CI (o 3 vs ⩾ 3: 28% vs 27%, P = 0.996). Patients transplanted with refractory disease reached a 1-year NRM of 34%, whereas 1-year NRM was 20% among CR patients (Table 2 and Figure 2 ). We found no difference in NRM according to conditioning regimen (TBI-based vs bu-based, Supplementary file 2A). Main cause of non-relapse deaths was infection (n = 6 (4 during aplasia, 2 after hematological recovery)), whereas four patients died from GVHD (two from acute and two from chronic forms, Table 3 ).
Relapse and survivals Disease progression occurred in 19 patients, in a median time of 123 days (range: 10-416 days). Only one patient relapsed after 1 year following Haplo-SCT. The overall 1-year cumulative incidences of relapse was 34%, 41% among AML patients and 14% among MDS patients. We found no difference in cumulative incidences of relapse according to conditioning regimen (TBI-based vs bu-based, Supplementary file 2B). With a median follow-up of 15 months (5-44 months), 1-year PFS, OS and GRFS were 39%, 50% and 37%, respectively (Table 2 and Figure 3 ). Patients transplanted in CR had 1-year PFS, OS (Table 2 and Figure 4 ) and GRFS of 47%, 62% and 47%, respectively. Patients transplanted with refractory disease reached a 1-year PFS, OS (Table 2 and Figure 4 ) and GRFS of 32%, 27% and 28%, respectively.
Sequential conditioning regimens Seven patients with refractory AML received intensive chemotherapy before bu-based RIC regimen. They presented with a median bone marrow blast count of 60% (range: 22-79%) before the fludarabine, idarubicin and cytarabine debulking chemotherapy. Three patients were evaluable by bone marrow aspirate before RIC regimen administration, all of them showed profound bone marrow hypoplasia with no blasts. Two patients died from severe infection during aplasia and five were in CR after hematological recovery following Haplo-HSCT. At the end of the follow-up, three died from AML relapse, whereas the two remaining patients were alive in CR at 11 and 14 months after Haplo-HSCT.
DISCUSSION
In this report, we analyzed the results of our PT-Cy Haplo-SCT program for high-risk AML and MDS. We confirmed the feasibility of PT-Cy Haplo-SCT with very low incidences of grade 3-4 acute GVHD (2%) and severe chronic GVHD (4%).This must be appreciated taking into account most of patients received PBSC as graft source (80%), confirming the absence of increased incidence of GVHD compared with bone marrow graft. 17 Considering the very advanced characteristics of our patients (HCT-CI ⩾ 3: 63%, age ⩾ 60 years: 45%; refractory disease: 50%; previous Allo-HSCT: 17%), the cumulative incidence of NRM (27% at 1 year) seems comparable to the results observed in the setting of HLA-identical Allo-HSCT for advanced diseases and/or high-risk patients. 16, 18, 19 We suggest that the use of PT-Cy explained in part this result. Indeed, PT-Cy was reported as effective GVHD prophylaxis, contributing to the overall improvement of outcomes after Haplo-SCT. These important findings make that the use of PT-Cy was recently extended to the setting of HLA-identical transplantations. 20, 21 Finally, better knowledge on immune recovery after PT-Cy Haplo-SCT could be useful for both prophylaxis and management of infectious complications. 22, 23 We found a cumulative incidence of relapse of 34% that is encouraging considering that all of our patients had criteria for high-risk disease (notably 50% refractory disease) and no other treatment alternative. As for comparison, we previously reported the outcome of 165 patients with AML/MDS who underwent Allo-HSCT from a matched, related or unrelated donor. 24 In this series, the cumulative incidence of relapse was 24% at 1 year, considering that only 5% of the AML patients were not in CR at the time of Allo-HSCT. In the present report, we found promising survivals in patients who underwent Haplo-SCT in CR (PFS: 47%, OS: 62%), although these patients still had criteria for high-risk disease (high-risk cytogenetics, advanced CR, acute transformation from MDS, previous allo-HSCT). This result suggests that Haplo-SCT could be considered as an effective option in consolidation phase of high-risk AML or MDS patients. We suppose that these results could be improved in AML patients with standard risk (that is, Intermediate cytogenetics AML in CR1), but to date, very few data of PT-Cy Haplo-SCT are available in this specific setting. The others series reporting the results of PT-Cy Haplo-SCT in the specific fields of AML or MDS included few patients (18) (19) (20) (21) (22) (23) (24) (25) , with various proportion of refractory diseases (36-100%). [25] [26] [27] They found a PFS ranging from 39 to 72%. More recently, Bacigalupo et al. reported promising results in AML and MDS, especially when Haplo-SCT was performed in CR1. 28 Finally, a CIBMTR registry analysis reported 192 AML patients who underwent PT-Cy Haplo-SCT, with similar outcome but lower chronic GVHD compared with matched unrelated donor Allo-HSCT. 29 Taken together, these results suggest that PT-Cy Haplo-SCT is feasible and effective in high-risk patients with AML or MDS who lack HLA-matched donor. We suppose that the anticipated high incidence of relapse after Haplo-SCT may be due to the advanced characteristics of patients rather than the procedure itself. This is supported by the results of ATG-based Haplo-SCT reported by other teams, showing better disease control in younger patients with less advanced diseases. [30] [31] [32] [33] [34] Our work has strengths and limitations. Its strengths include the relatively high number of patients compared with previous reports of PT-Cy Haplo-SCT for AML or MDS in the literature. Moreover, the fact that most of our patients received PBSC as graft source also provides additional information in the field of PT-Cy Haplo-SCT that commonly use bone marrow grafts. Our study also had limitations that are related to its retrospective nature. Because of the evolution of our transplantation program over years, different types of conditioning regimens were used. We found no difference in disease control and outcome when comparing the fludarabine-TBI non-myeloablative conditioning to the bu-based regimens, but the low number of patients and the baseline characteristic heterogeneity did not allow us to clearly address this comparison. Comparative studies are needed to really assess the role of conditioning intensity on disease control after Haplo-SCT. We acknowledge that the role of Haplo-SCT should be reassessed in the different disease-specific subgroups for which the anticipated benefit might be different. Moreover, subsequent analyses with longer follow-up are needed to evaluate both long-term toxicities and disease control after Haplo-SCT.
We conclude that even in very high-risk myeloid malignancies, disease control can be achieved. Our results suppose that in less advanced situation, disease control is eventually much better, conducting to satisfactory outcomes. Both results support that Haplo-SCT really exerts an efficient tumor control contradicting initial concerns on this matter. Thus, Haplo-SCT could be safely extended to patients without HLA-identical donor without impairing disease control. Prospective studies are needed to better evaluate the impact of Haplo-SCT in the treatment strategy of AML and MDS.
